In this article, we break down the Top 5 Biotech Stocks to Buy With Up to 215% Projected EPS Growth. In this piece, we take a closer look at Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.
The biotech sector is again becoming one of the most watched corners of the stock market this May 2026, and frankly, it is not hard to see why. In a market where investors are constantly hunting for the next big growth story, biotechnology stocks offer something very different from ordinary consumer, banking, or industrial names. These companies are not only selling products. They are trying to solve medical problems, develop new therapies, improve diagnostics, and push modern medicine into areas that once sounded impossible.
That is why biotech stocks remain attractive, risky, and fascinating at the same time. A single clinical trial update, regulatory approval, earnings surprise, or breakthrough treatment can completely change the direction of a stock. On the other hand, one failed study, delayed approval, weak reimbursement decision, or heavy cash burn can quickly destroy investor confidence. This is the uncomfortable truth of biotech investing: the upside can be huge, but the risks are just as real.
The Big Appeal: Science, Medicine, and Market Upside in One Sector
Biotech stocks are different because their value is often tied to future medical breakthroughs. Some companies focus on gene editing, while others work on rare disease treatment, cancer diagnostics, immunology, neurology, dermatology, transplant testing, genomic medicine, and precision healthcare. These are not small themes. They are part of a much bigger shift in global healthcare, where treatment is becoming more personalized, more data-driven, and more dependent on advanced biological science.
This is also why investors continue searching for the best biotech stocks to buy now, especially as aging populations, rising healthcare needs, and demand for better treatments create long-term growth opportunities. In simple terms, people are living longer, chronic diseases are becoming more common, and healthcare systems need better tools to diagnose, treat, and monitor patients. That gives the biotechnology sector a strong long-term foundation, even if short-term stock prices remain volatile.
Why May 2026 Matters for Biotech Investors
May 2026 is shaping up to be another important period for biotech investors because the market is becoming more selective. During easy-money periods, many speculative biotech stocks can rise simply because investors are excited about future potential. But in a tougher market, investors usually become more careful. They start looking more closely at fundamentals, projected earnings growth, sales growth, cash runway, commercial execution, clinical progress, and analyst ranking signals.
That is why the current biotech stock discussion is not only about hype. It is about quality. Investors are paying attention to companies with stronger research engines, improving revenues, better test volume growth, more durable reimbursement opportunities, and clearer paths toward profitability. The best biotech stocks in 2026 are not necessarily the loudest names. They are often the companies that can show real progress, whether through commercial sales, expanding clinical evidence, stronger adoption by physicians, or better financial discipline.
The Risk-Reward Equation Is Still the Heart of Biotech Investing
Biotech investing has always been a high-risk, high-reward game. That has not changed. What makes the sector exciting is the possibility that one successful product, test, platform, or therapy can unlock major growth. But what makes it dangerous is the fact that many companies spend heavily on research and development before they ever generate meaningful profit.
This is why long-term investors usually need to study more than just stock price movements. A biotech stock can look cheap after a major decline, but that does not automatically make it a bargain. Investors need to ask tougher questions. Does the company have enough cash to fund operations? Is the pipeline strong? Are sales growing? Are doctors adopting the product? Are payers supporting reimbursement? Is management controlling costs? Are earnings estimates improving or weakening? Is the company dependent on one product, or does it have multiple shots on goal?
Those questions matter because biotech stocks can move quickly in both directions. The best opportunities often come from companies where the market is underestimating future growth, while the biggest traps often come from companies where the story sounds exciting but the numbers are not yet strong enough.
Precision Medicine, Gene Therapy, and mRNA Are Changing the Sector
One major reason biotech stocks continue to attract attention is the rise of precision medicine. Instead of treating every patient the same way, the industry is moving toward more targeted approaches based on genetics, biomarkers, disease subtype, and patient-specific data. This is already changing areas like cancer testing, rare disease treatment, autoimmune disease research, and transplant monitoring.
Gene therapy and gene editing are also reshaping investor expectations. These technologies aim to treat diseases closer to their biological root cause instead of only managing symptoms. Meanwhile, mRNA technology, which became globally recognized during the pandemic era, continues to influence how investors think about vaccine development, infectious disease research, cancer immunotherapy, and future drug platforms.
These themes are not just scientific trivia. They are market-moving trends. The more these technologies mature, the more investors will look for companies that can translate scientific innovation into commercial revenue, regulatory wins, and long-term shareholder value.
Why Fundamentals Matter More Than Ever
The best biotech stocks to buy for May 2026 are being judged on a blend of signals, not just one attractive headline. Price performance matters because it shows whether the market is starting to reward a company. Forward price-to-earnings ratios matter because they give investors a sense of valuation. Projected earnings growth matters because biotech companies need to prove they can scale. Projected sales growth matters because innovation eventually needs to become revenue.
This is where biotech becomes more interesting than pure speculation. A company with strong sales growth, improving profitability, better clinical adoption, and a reasonable valuation may be more attractive than a stock that only has a dramatic pipeline story. At the same time, some high-growth biotech names may look expensive based on traditional metrics because investors are already pricing in future success. That is why ranking biotech stocks requires a balanced view of growth, valuation, risk, research momentum, and financial execution.
READ THIS TOO: Top 5 Best Biotech Stocks To Watch Now
The Investor Question: Breakthrough Opportunity or Speculative Trap?
For investors, the big question is simple: are biotech stocks a good long-term investment? The honest answer is yes, but only for those who understand the risks. Biotech stocks can deliver extraordinary returns when clinical programs succeed, products gain adoption, and revenues accelerate. But they can also disappoint badly when trials fail, approvals are delayed, margins weaken, or investor expectations run too far ahead of reality.
This is why the biotech sector is not ideal for investors who cannot handle volatility. Stock prices can swing sharply because the market reacts quickly to scientific data, analyst changes, earnings results, regulatory decisions, and management guidance. But for investors with patience, research discipline, and enough risk tolerance, the sector can offer compelling long-term opportunities.
The best approach is not to chase every hot biotech headline. It is to focus on companies with stronger fundamentals, clearer growth drivers, meaningful exposure to high-value medical markets, and enough financial strength to survive the long and expensive road of healthcare innovation.
Why These Biotech Stocks Deserve Attention Now
This May 2026 list focuses on biotech stocks that combine scientific relevance with market signals such as price movement, projected sales growth, projected earnings growth, valuation, and ranking strength. These companies are tied to major healthcare themes, including cancer diagnostics, rare disease treatment, neurological disorders, transplant medicine, dermatology, genomic testing, and advanced therapeutic platforms.
The key point is that biotech investing is no longer only about guessing which company will produce the next miracle drug. It is also about identifying businesses that can manage research spending, grow revenue, protect reimbursement, expand clinical use cases, and build stronger commercial platforms. In today’s market, that discipline matters.
For investors searching for the best biotech stocks to buy now, top biotech stocks for May 2026, high-growth biotech stocks, biotech stocks with strong upside potential, and long-term healthcare stocks, this sector remains one of the most exciting but demanding areas of the market. The opportunity is real, but so is the risk. That is why every name on the list deserves a closer look, not just because of its stock price, but because of the science, strategy, and financial story behind it.
CHECK THIS OUT: Top 10 Best Biotech Microcap Stocks That Could Explode 10X in 2026. and Top 10 Biotech Stocks That Could Deliver 1,000% Returns.
Our Methodology
To compile this list of the top 5 biotech stocks to buy with up to 215% projected EPS growth, our team reviewed biotech companies using recent price performance, valuation metrics, projected EPS growth, projected sales growth, ranking signals, fundamentals, and each company’s exposure to high-growth healthcare themes such as precision medicine, rare disease treatment, diagnostics, and advanced therapeutics.
Top 5 Biotech Stocks to Buy With Up to 215% Projected EPS Growth
1. Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)
Arcutis Biotherapeutics takes the top spot in this May 2026 biotech list because the growth numbers are hard to ignore. Based on the provided data, the stock was priced at $21.17, with a 12-week price change of -18.14%, a forward P/E of 141.13, projected one-year EPS growth of 215.38%, and projected sales growth of 32.53%. That setup is exactly why Arcutis is interesting and risky at the same time. The valuation looks stretched, and the stock has pulled back recently, but the projected earnings growth and product revenue momentum make it one of the most exciting commercial-stage biotech names on the list.
Arcutis is focused on immuno-dermatology, which may sound less dramatic than oncology or rare disease biotech, but the commercial opportunity is very real. Skin diseases such as psoriasis, seborrheic dermatitis, and atopic dermatitis affect large patient populations and can create recurring treatment demand. The company’s key product family is ZORYVE, a roflumilast-based treatment platform offered in different formulations and strengths. For investors, the main question is whether ZORYVE can keep gaining share in branded topical treatments while Arcutis expands into more patient groups and prescriber channels.
The company’s first-quarter 2026 results showed strong year-over-year growth. Arcutis reported ZORYVE net product revenue of $105.4 million, up 65% compared with the first quarter of 2025, although it was down 17% from the fourth quarter of 2025 due mainly to typical first-quarter deductible resets and insurance changes. That seasonal decline matters, but the bigger year-over-year trend remains strong.
The revenue breakdown also gives investors more color. In the first quarter, ZORYVE cream 0.3% generated $32.7 million, ZORYVE topical foam 0.3% generated $49.6 million, ZORYVE cream 0.15% generated $21.7 million, and ZORYVE cream 0.05% generated $1.4 million. The company said the year-over-year growth was driven by strong unit demand and improvements in gross-to-net sales deductions.
Management said demand remained strong despite normal first-quarter seasonality. The company also said ZORYVE continues to grow its share of branded non-steroidal topical treatments. That detail matters because steroid-free dermatology options can be attractive to patients and physicians looking for alternatives in chronic inflammatory skin conditions. Investor’s Business Daily also reported earlier this year that Arcutis had received its sixth FDA approval for ZORYVE cream in dermatitis patients as young as two years old, which strengthened its profile in pediatric dermatology.
Arcutis is also working to expand the ZORYVE opportunity further. The company submitted a supplemental New Drug Application to the FDA for ZORYVE cream 0.05% to expand use in atopic dermatitis patients ages 3 to 24 months. It also completed enrollment in the ZORYVE foam 0.3% maximum usage systemic exposure trial in children ages 2 to 11 years with plaque psoriasis of the scalp and body. These pediatric expansion efforts could become important if approvals widen the addressable market.
The company has also moved into the next phase of commercial execution. Arcutis completed its dermatology sales force expansion at the beginning of May and started building a primary care and pediatrics-focused organization. This is a key operating detail because many biotech companies can win approval but struggle with commercialization. Arcutis is now trying to deepen prescriber adoption and improve reach, especially as it expands into broader dermatology and pediatric channels.
Another important point: Arcutis maintained positive operating cash flow for the quarter. For a fast-growing biotech company, that is a meaningful signal. Investors are watching not only revenue growth but also whether the company can support its commercial push without constantly relying on fresh capital.
READ ALSO: Top 10 Biotech Stocks That Could Explode in 2026 and Top 10 Small-Cap FDA Catalyst Biotech Stocks.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
